Best Diversified Diagnostics Companies in United States
The 369 best Diversified Diagnostics companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LumiraDx.
Ranking the most-funded Diversified Diagnostics companies in the United States, this directory tracks 369 ventures carrying $2.1B in disclosed equity across a market forecast to grow from roughly $3.0B to $4.5B by 2030, a 4.7% CAGR shaped by rising chronic-disease burdens and the spread of point-of-care testing. No unicorns here. What you do get is a funding stack led by Interpace Biosciences at $72M, Vergent Biosciences at $35M, and Lohocla at $22M, with institutional backers like the NIH, HHS, and the National Science Foundation doing a lot of the heavy lifting.
The revenue picture is where things get clarifying. Median revenue across validated filers sits at $3M, with a punishing -23% YoY contraction, and yet the combined pool still clears $247M. Gen Probe pulls $153M of that, 61 times the sector median. Abaxis adds $68M. So when I say the scale is uneven, I mean structurally, almost comically so. Stringent regulatory approval requirements slow entrants and widen the gap between established earners and early-stage filers, which explains why so much of this directory's funding traces back to grant-heavy public sources rather than commercial momentum.
- ResearchAndMarkets.com
Ranked: Best Diversified Diagnostics companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LumiraDx Cloud based diagnostics platform for point of care diagnosing | $704M | 42 mo ago | 8 | 2014 | Sumit Nagpal Co-Founder & CEO | Apple iCloud MailMicrosoft 365Node.js+17 | 4 patents Microfluidic sample handling and optical detection for point‑of‑care diagnostic assays. | — |
| 2 | Millenium Health Systems Drug testing laboratory empowering clinicians with comprehensive data insights for patient care | $196M | 190 mo ago | 484 | 2007 | — | WordPressApple iCloud MailMySQL+24 | — | — |
| 3 | Navidea Biopharmaceuticals Developer of immunodiagnostic agents and immunotherapeutics for cancer and inflammatory diseases | $111M | 63 mo ago | 14 | 1983 | Michael Goldberg CEO | BootstrapApache HTTP ServerjQuery+7 | 153 patents Mannose‑decorated dextran nanocarriers for CD206‑targeted drug delivery to macrophages | — |
| 4 | Interpace Biosciences Provider of molecular diagnostic tests and pathology services for cancer diagnosis | $72M | 20 mo ago | 94 | 1986 | Thomas Burnell CEO & President | Apple iCloud MailLeafletBootstrap+16 | — | — |
| 5 | QuidelOrtho Provider of diagnostic healthcare products, ranging from home to hospital use | $69M | 53 mo ago | 7,000 | 1937 | Douglas Bryant CEO | Adobe Experience ManagerJavaBootstrap+18 | — | 1 job opening |
| 6 | LightDeck Diagnostics Developer of point-of-care diagnostic device for multiplex assays | $56M | 48 mo ago | 80 | 2009 | Nick Traggis CEO | — | — | — |
| 7 | TriVirix Diversified medical device company offering contract manufacturing services | $49M | 202 mo ago | — | 1998 | Paul Fink CEO | — | — | — |
| 8 | Nodality Discovers and develops personal diagnostics | $49M | 178 mo ago | 25 | 2006 | David Parkinson President and CEO | — | 145 patents Immunodiagnostic assays and immunomodulatory therapeutics targeting JAK/STAT pathways | — |
| 9 | ONTERA Provider of a range of diagnostic devices based on nanopore technology | $45M | 70 mo ago | 37 | 2011 | — | — | 55 patents Nanopore-based detection and quantification of nucleic acid sequences and variants | — |
| 10 | Babson Diagnostics Provider of blood testing service using microsamples collected from a finger. | $45M | 59 mo ago | 57 57 → 54 (-5%) | 2017 | Eric Olson Founder | Craft CMSPHPUbuntu+12 | 22 patents Automated blood sample handling and centrifugation for point‑of‑care diagnostics | 1 launch · 1 partnership |
| 11 | Cylex In vitro assays for diagnostics | $42M | 189 mo ago | 27 | 1992 | Brad Stewart CEO | — | 6 patents Immune response monitoring assays for disease and transplant outcome diagnostics | — |
| 12 | General Fluidics Vitro diagnostic company | $35M | 23 mo ago | 14 | 2011 | Robert Granier CEO | — | — | 1 partnership |
| 13 | Vergent Biosciences Developing tumor-targeted imaging agents for improved cancer surgery outcomes | $35M | 8 mo ago | 10 | 2014 | — | — | — | — |
| 14 | Interleukin Genetics Genetic tests for personalized medicineIn | $34M | 118 mo ago | 14 | 1997 | Lew Bender Co-CEO | — | 168 patents Genetic diagnostic biomarkers for obesity, cardiovascular, osteoarthritis, and periodontal disease risk | — |
| 15 | HistoWiz Automated histopathology services accelerating research with digital pathology solutions | $33M | 55 mo ago | 65 | 2012 | — | — | 8 patents AI-driven image analysis for automated tagging and quality control of digital pathology slides | 1 launch · 1 partnership |
| 16 | Celerus Diagnostics Singapore Togel results, data, and prize information provider | $27M | 177 mo ago | 11 | 2004 | — | — | 29 patents Automated rapid immunohistochemistry using advanced fluidic and heating technologies | — |
| 17 | Cholestech Point-of-care diagnostic solutions for lipid, cholesterol, and glucose testing | $24M | 424 mo ago | 73 | 1988 | — | — | 48 patents Point‑of‑care lipid and cholesterol immunoassay cassettes for serum analysis | — |
| 18 | Chronus Health Provider of Healthcare diagnosis services | $24M | 53 mo ago | 21 | 2017 | Ashish Jagtiani Co-Founder and CTO | — | — | — |
| 19 | CyVek Automated immunoassay systems | $22M | 146 mo ago | 40 | 2008 | — | — | 69 patents Microfluidic assay platforms and manufacturing methods for high‑throughput biochemical testing. | — |
| 20 | ProciseDx Provider of a point-of-care clinical diagnosis device for healthcare professionals | $22M | 59 mo ago | 25 | 2018 | — | — | 36 patents Immunoassay diagnostics for vascular biomarkers, therapeutic antibodies, and viral antibodies. | — |
| 21 | Lohocla Developing multi-target therapeutics for chronic pain, neuroinflammation, and addiction | $22M | 13 mo ago | 5 | 1983 | Boris Tabakoff Founder & CEO | — | — | — |
| 22 | EraGen Biosciences Molecular Reagent Products and molecular diagnostic products for early detection and monitoring of cancer… | $21M | 213 mo ago | 50 | 1994 | — | — | 49 patents Patents concentrated in chemistry & materials | — |
| 23 | NanoDx Manufacturer of diagnostic medical equipment and tests | $18M | 71 mo ago | 34 | 2010 | Brian Mcglynn Co-Founder & CTO | — | 39 patents Capacitive electrical sensor systems for precise measurement of sensor electrical characteristics | — |
| 24 | Navigenics Premier online platform for live sports streaming, news, and analysis | $18M | 196 mo ago | — | 2006 | Dietrich Stephan Co-Founder | — | 43 patents Personalized genetic risk assessment and actionable health decision-support systems. | — |
| 25 | Curve Biosciences Provider of manufacturing diagnostic kits for multiple therapeutic areas | $18M | 7 mo ago | 10 | 2020 | Chuba Oyolu Co-Founder & CTO | — | — | 1 launch |
| 26 | Reveal Pharmaceuticals Gadolinium-free MRI contrast agents for safer medical imaging and diagnostics | $16M | 36 mo ago | 8 | 2016 | Peter Caravan Co-Founder | — | — | — |
| 27 | Ohmx Corporation Point-of-Care device for diagnosis and monitoring of chronic disease patients | $15M | 100 mo ago | 3 | 2010 | Charlie Pennington CEO | — | 96 patents Point‑of‑care bioelectronic diagnostic assays and biosensor platforms for clinical biomarkers | — |
| 28 | Nexus Dx Global provider of near-patient testing systems and advanced diagnostic solutions | $15M | 200 mo ago | 24 | 2009 | Nam Shin President & Chief Executive Officer | — | 121 patents Microfluidic point‑of‑care diagnostic platforms integrating thin‑film centrifugation and ELISA assays | — |
| 29 | Cordant Health Solutions Company offering drug testing services for a wide range of applications including clinical trial testing | $13M | 134 mo ago | 358 | 2012 | — | WordPressMySQLPHP+27 | — | — |
| 30 | Robin Medical MRI tracking systems for enhanced medical imaging and intervention | $13M | 105 mo ago | — | 1997 | Erez Nevo Founder & CEO | — | — | — |
| 31 | Flagship Biosciences Digital pathology solutions for the biopharmaceutical industry | $12M | 26 mo ago | 79 | 2009 | — | WordPressMySQLPHP+20 | 39 patents AI-driven digital pathology: multi-test scoring and image alignment for tissue diagnostics | — |
| 32 | MatMaCorp Developer of portable and molecular testing solutions | $11M | 84 mo ago | 16 | 2014 | Abraham Oommen Founder & CEO | — | — | — |
| 33 | ReaMetrix In Vitro diagnostics platform | $11M | 198 mo ago | 3 | 2003 | Bala S Manian Founder & CEO | — | 47 patents Optical biosensing and porous planar cell capture for viable microorganism detection | — |
| 34 | Cerescan Provider of quantitative SPECT brain imaging protocol and legal support services | $11M | 73 mo ago | 16 | 2008 | — | — | 5 patents AI-driven neuroimaging data storage, retrieval, and analysis platforms | — |
| 35 | Rapid Diagnostek Biosensor-based point of care diagnostics platform | $10M | 135 mo ago | 11 | 1986 | — | — | 34 patents Patents concentrated in computing, sensing & instrumentation | — |
| 36 | STRM.BIO R&D company focused on manufacturing gene therapy diagnostic tests for multiple therapeutic areas | $10M | 5 mo ago | 23 | 2019 | Jonathan Thon Founder | — | — | 1 launch |
| 37 | Inherent Biosciences Developer of epigenetic diagnostics and therapeutics for complex diseases | $9M | 14 mo ago | 15 | 2019 | Kristin Brogaard Co-Founder & CSO | — | — | — |
| 38 | iSense Advanced sensors for chemical detection in liquids and vapors | $8M | 105 mo ago | — | 2008 | Paul Rhodes CEO | — | 177 patents Minimally invasive insertion of nucleophilic chemical sensor arrays for continuous physiological monitoring. | — |
| 39 | LighTopTech High-resolution nondestructive imaging solutions using biomimetic microscope design and liquid lens technology | $6M | 88 mo ago | 5 | 2013 | Cristina Canavesi Co-Founder & President | — | 8 patents High‑resolution 3D optical coherence tomography and microscopy for dynamic and corneal imaging | — |
| 40 | Enable Biosciences Predictive medicine tools for early disease detection and improved healthcare | $5M | 29 mo ago | 14 | 2015 | David Seftel Md CEO / CFO / CMO | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | — |
| 41 | Expansion Technologies Innovating brain research through advanced microscopy and simulation technologies | $4M | 16 mo ago | 2 | 2015 | Ed Boyden Co-Founder | — | 2 patents Pipe/tube expansion devices for mechanical deformation and fabrication processes. | — |
| 42 | SonoSite Point-of-care ultrasound solutions provider, empowering clinicians with advanced imaging | $3M | 33 mo ago | 606 | 1986 | — | DrupalPHPSalesforce+16 | 187 patents Advanced ultrasound imaging, beamforming, vascular measurement, and instrument detection technologies. | — |
| 43 | Precidiag AI-enabled precision medicine biotech discovering microbiome-inspired therapeutics for complex diseases | $3M | 45 mo ago | 12 | 2015 | Jian Shao Co-Founder & CEO | — | 2 patents Microbial biomarker profiling for autism spectrum disorder diagnostics | — |
| 44 | PERSOWN AI and cloud-based interoperable platforms for providers and patients | $3M | 23 mo ago | 25 | 2020 | William Meadow Co-Founder | — | 5 patents Electrochemical diagnostic devices and methods for medical/clinical testing | — |
| 45 | TETmedical Developer of nanomedicine in-vitro diagnostics for high-consequence disease decision making | $2M | 30 mo ago | — | 2021 | Roy Cohen Co-Founder | — | 4 patents Tethered enzyme biosensor platforms for enzymatic activity detection of clinical biomarkers | — |
| 46 | Burst Diagnostics Manufacturer of paper-based diagnostic assay kits | $2M | 15 mo ago | 8 | 2020 | Charles Henry CEO | — | — | — |
| 47 | Novel Dx Hand held molecular diagnostic platform | $2M | 2 mo ago | 26 | 2014 | Andrea Pais Founder & CEO | WordPressMySQLPHP+21 | — | 1 job opening |
| 48 | Pace Diagnostics Developer of point-of-care rapid diagnostics for tuberculosis, COVID-19, and lung cancer | $2M | 9 mo ago | 8 | 2017 | Lorne Mattner Co-Founder & COO | — | — | — |
| 49 | Quasar Innovating dry EEG sensors and psychophysiological monitoring systems for diverse applications | $1M | 16 mo ago | — | 1997 | Walid Soussou CEO | — | 7 patents Patents concentrated in health & consumer products | — |
Top 12 Diversified Diagnostics companies in United States
#1
Series B · Minneapolis, Minnesota · founded 2014 · 10 employees$34.6Mraised▾
Developing tumor-targeted imaging agents for improved cancer surgery outcomes. The company is a clinical-stage biotechnology firm focused on enhancing cancer surgery through improved tumor visualization. They are developing tumor-targeted fluorescent imaging agents designed to help surgeons see previously undetected or difficult-to-find tumors in real-time during minimally invasive and robotic-assisted surgery. Their lead compound is being evaluated in lung cancer, with potential applications across a range of solid tumors. The goal is to improve the visibility of tumors, enabling more complete removal of cancerous tissue. This innovative approach aims to make cancer surgery more successful for surgeons and patients, increasing the therapeutic potential of surgery as a first-line treatment for solid tumors. The company is committed to rigorous science and aims to become a leader in intraoperative tumor visualization.
- Oct 2025Series B$18.7M
- Feb 2025Series B$3.8M
- Oct 2022Series B$21.5M
- Sep 2022Grant (prize money)$2M
#2
Seed · Cambridge, Massachusetts · founded 2019 · 23 employees$9.8Mraised▾
R&D company focused on manufacturing gene therapy diagnostic tests for multiple therapeutic areas
- Jan 2026Seed$8M
- Nov 2025Grant (prize money)$1.8M
#3
Series A · Washington, DC, District of Columbia · founded 2014 · 26 employees$2.4Mraised▾
Novel Micro Devices is a medical devices start-up currently incubated at the Baltimore Underground Science Space (BUGSS), developing a hand-held device for molecular diagnostics that will be capable of directly analyzing raw biological samples at the point of care to provide robust, qualitative diagnostic information in less than 30 minutes. The company hopes to develop applications for the platform in the area of POC diagnostics, biodefense, food safety, forensics, research, animal care and agriculture. Details of the technology are not available as of December 2017.
- Mar 2026Series A$1M
- Dec 2024Conventional Debt$567K
- Nov 2024Grant (prize money)$2.7M
- Dec 2023Series A$1.9M
#4
Series A · Mountain View, California · founded 2020 · 10 employees$17.7Mraised▾
Provider of manufacturing diagnostic kits for multiple therapeutic areas
- Oct 2025Series A$40M
- May 2024Seed$17.7M
#5
Funding Raised · Aurora, Colorado · founded 1983 · 5 employees$21.6Mraised▾
Developing multi-target therapeutics for chronic pain, neuroinflammation, and addiction. This company is dedicated to creating innovative medications to alleviate suffering from chronic pain, neuroinflammation, and addiction. They employ a "multi-target approach," modulating multiple neural systems simultaneously for superior action and safety compared to single-target drugs. Their research focuses on understanding the neural systems involved in these conditions to develop effective treatments. This approach aims to improve the lives of individuals worldwide, offering hope for those struggling with debilitating afflictions. They are committed to bringing life-changing medications to market, forging a new path towards wellness and recovery.
- May 2025Grant (prize money)$9.3M
- Jan 2025Grant (prize money)$5.1M
- Sep 2015Grant (prize money)$3.4M
- Jul 2013Grant (prize money)$316.5K
#6
Public · Parsippany Troy Hills, New Jersey · founded 1986 · 94 employees$72.1Mraised▾
Provider of molecular diagnostic tests and pathology services for cancer diagnosis. It offers molecular analysis for early cancer diagnosis and treatment. The company provides clinically beneficial, evidence-based molecular diagnostic tests and pathology services.
- Oct 2024Post IPO$47M
- Jan 2020Post IPO$20M
- Oct 2017Post IPO$5M
- Jan 2017Post IPO$111.2K
#7
Series A · Salt Lake City, Utah · founded 2019 · 15 employees$9.1Mraised▾
Developer of epigenetic diagnostics and therapeutics for complex diseases. It focuses on identifying dysregulation across multiple genes and related pathways. It aims to transform the diagnosis and treatment of complex diseases like infertility through its epigenetic platform. The company's initial product, SpermQT, seeks to improve fertility testing and provide personalized treatment plans.
- Apr 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$1.9M
- Jan 2025Grant (prize money)$1.9M
- Feb 2024Grant (prize money)$1M
#8
Series B · Boston, Massachusetts · founded 2011 · 14 employees$35.1Mraised▾
Developer of a vitro diagnostic tool designed for end-to-end, fully integrated modular IVD for performing a growing array of blood and urine tests. The company's platform uses a patented hybrid hardware architecture, fluidics, and optoelectronic technologies to go beyond test results to deliver complete diagnostic information sets at the point of care, enabling physicians to provide better treatments for neonatal and pediatric patients.
- Jul 2024Series B$18.5M
- Sep 2023Grant (prize money)$297.6K
- Jun 2022Series A$4.1M
- Dec 2020Series A$6.7M
#9
Acquired · Waltham, Massachusetts · founded 2014 · 8 employees$703.9Mraised▾
LumiraDx a healthcare solutions care management company specializing in the comprehensive support of individuals with chronic disease. The flagship software solutions called "Consult" allow health and social care providers to view and manage patient records that are always joined up across all venues of care, from the doctor’s office to a patient’s home. The patient-facing version of this software "Engage" allows individuals to view, manage, and share their own history from across all venues of care. Their platform also connects with a growing list of home and point-of-care diagnostic devices and personal biometric devices that record real-time activity including continuous heart rate, surface temperature, posture, sleep, stress levels and integrates this data into individual longitudinal records.
- Dec 2022Grant (prize money)$14.2M
- Apr 2021Conventional Debt$400M
- Dec 2020Series D$164M
- May 2020Series C$150M
#10
Seed · Monrovia, California · founded 2017 · 8 employees$1.9Mraised▾
Developer of point-of-care rapid diagnostics for tuberculosis, COVID-19, and lung cancer. It focuses on researching, developing, licensing, manufacturing, and marketing diagnostics. It develops point-of-care rapid diagnostics through novel biomarkers and innovative diagnostic platforms.
- Aug 2025Grant (prize money)$300K
- Oct 2017Seed$1.6M
#11
Series A · Cambridge, Massachusetts · founded 2015 · 2 employees$3.5Mraised▾
Innovating brain research through advanced microscopy and simulation technologies. The company pioneers computer simulations of the human brain, leveraging connectivity and molecular insights to revolutionize AI development, brain disease treatment, and our understanding of the human condition. They achieve this through novel tools, including expansion microscopy, optogenetics, and high-speed brain activity imaging. Expansion microscopy, a core invention, enables nanoprecise imaging of large-scale brain tissues with molecular information. This technology permeates brain tissue and physically expands it, allowing for detailed analysis. The company's work has potential social impact in healthcare and technology, pushing the boundaries of neuroscience and offering new avenues for research and discovery.
- Feb 2025Grant (prize money)$500K
- Sep 2022Grant (prize money)$500K
- Nov 2017Series A$1.5M
- Feb 2016Series A$2M
#12
Seed · Fort Collins, Colorado · founded 2020 · 8 employees$2.4Mraised▾
Manufacturer of paper-based diagnostic assay kits
- Feb 2025Grant (prize money)$279.6K
- Jan 2024Seed$2.4M
- Aug 2023Grant (prize money)$279.6K
- Mar 2023Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Diagnostics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.